Hyperpigmentation is one of the most common presenting concerns in UK aesthetic clinics, and it disproportionately affects patients with darker skin tones (Fitzpatrick types IV-VI). Treating these patients requires specialised knowledge, carefully selected ingredients, and protocols designed to improve pigmentation without triggering further damage.
Understanding Hyperpigmentation in Darker Skin
Melanocytes in darker skin are larger, more active, and more reactive to inflammation. This means that conditions like melasma, post-inflammatory hyperpigmentation (PIH), and solar lentigines are not only more prevalent but also more challenging to treat. Any treatment that causes inflammation, even mild irritation, risks triggering a paradoxical darkening response. The guiding principle is always "first, do no harm."
Safe Active Ingredients
Evidence-based ingredients for darker skin tones include alpha arbutin, which inhibits tyrosinase without the risks of hydroquinone and is safe for long-term use. Azelaic acid at 15-20% concentration addresses both pigmentation and inflammation, making it ideal for PIH. Niacinamide at 5-10% reduces melanosome transfer to keratinocytes while strengthening the barrier. Tranexamic acid, both topical and oral, has shown remarkable results for stubborn melasma in darker skin. Vitamin C in stabilised L-ascorbic acid form provides antioxidant protection and mild brightening. These ingredients form the core of Skymedic's depigmenting protocols, available in our drug delivery serum range.
Ingredients and Treatments to Approach with Caution
Hydroquinone above 2% should be used under close supervision and for limited durations. High-strength chemical peels, particularly TCA above 15%, carry significant PIH risk. Aggressive laser treatments, especially those targeting melanin, can cause permanent depigmentation in darker skin. IPL is generally contraindicated in Fitzpatrick V-VI skin types.
Recommended Protocol
A safe and effective protocol for hyperpigmentation in darker skin tones involves three phases. During the preparation phase lasting 4-6 weeks, introduce niacinamide and azelaic acid to calm inflammation and begin inhibiting excess melanin production. The active treatment phase of 8-12 weeks adds alpha arbutin and vitamin C serums, with optional light mesotherapy using Skymedic's brightening cocktails. The maintenance phase involves ongoing use of depigmenting actives at maintenance doses, paired with strict SPF 50+ sun protection.
The Importance of Sun Protection
In darker skin, UV exposure is the primary trigger for melasma flares and PIH recurrence. Daily SPF 50+ application is non-negotiable, regardless of weather or season. Skymedic's Fotoskinox range includes tinted formulations designed to blend seamlessly with darker skin tones.
For clinical training on treating diverse skin types, register as a Skymedic professional to access our educational resources and product protocols.
